These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18366982)

  • 21. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
    Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
    Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrates: where are we now?
    Seth Loomba R; Arora R
    Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
    Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
    Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
    Ansquer JC; Foucher C; Aubonnet P; Le Malicot K
    Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF; Dimmitt SB
    Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention.
    Chapman MJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):135-9. PubMed ID: 16025232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
    Robins SJ
    Curr Opin Lipidol; 2003 Dec; 14(6):575-83. PubMed ID: 14624134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
    Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
    Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
    McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
    Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.
    Farnier M
    Vasc Health Risk Manag; 2008; 4(5):991-1000. PubMed ID: 19183747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.
    Koh KK; Quon MJ; Rosenson RS; Chung WJ; Han SH
    Int J Cardiol; 2008 Feb; 124(2):149-59. PubMed ID: 17658632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypertriglyceridemia Therapy: Past, Present and Future Perspectives.
    Canfora I; Pierno S
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Pehlivanidis AN; Kontopoulos AG
    J Cardiovasc Risk; 2002 Feb; 9(1):33-9. PubMed ID: 11984215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
    Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
    Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrates and niacin: is there a place for them in clinical practice?
    Wierzbicki AS; Viljoen A
    Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
    Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
    Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.